ADPT new logo.jpg
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
March 27, 2024 08:30 ET | Adaptive Biotechnologies
SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
February 22, 2024 16:05 ET | Adaptive Biotechnologies
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024 16:05 ET | Adaptive Biotechnologies
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
ADPT new logo.jpg
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
January 29, 2024 16:05 ET | Adaptive Biotechnologies
SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023 16:05 ET | Adaptive Biotechnologies
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
ADPT new logo.jpg
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
December 09, 2023 08:30 ET | Adaptive Biotechnologies
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator...
ADPT new logo.jpg
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
December 05, 2023 07:30 ET | Adaptive Biotechnologies
Data supporting clonoSEQ’s clinical and research utility, as well as insights based on analysis of real-world experience, will be featured at ASH.
ADPT new logo.jpg
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 16:05 ET | Adaptive Biotechnologies
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
ADPT new logo.jpg
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 07, 2023 07:30 ET | Adaptive Biotechnologies
Data generated by Adaptive’s next-generation sequencing-based MRD assay will support the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, Nov. 07,...
ADPT new logo.jpg
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
November 02, 2023 16:05 ET | Adaptive Biotechnologies
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...